期刊文献+

硝苯地平的生物利用度研究 被引量:1

Study on the Bioavailability of Nifedipine
下载PDF
导出
摘要 目的考察硝苯地平的生物利用度。方法建立测定大鼠血浆中硝苯地平的HPLC方法测定血药浓度,静脉注射硝苯地平(剂量0.75mg·kg^(-1))与口服给药硝苯地平(剂量3mg·kg^(-1))测定血药浓度。结果经拟合得出i.v.符合两室模型,i.g.符合一室模型,计算绝对生物利用度为38.02%。结论结果表明硝苯地平在大鼠体内的绝对生物利用度较低。 OBJECTIVE To study the bioavailability of nifedipine. METHODS To establish a HPLC method for the determination of nifedipine in rats plasma. The blood drug concentration was determined after intravenous in- jection of nifedipine (0.75mg · kg^-1 ) and oral administration of nifedipine (3mg · kg^-1 ). RESULTS The resluts showd that oral administation met one compartment model and intravenous administration met two compartment mod- el. The absolute bioavailability is 38.02%. CONCLUSION The results showed that the absolute bioavailability of nifediDine was low in rats.
出处 《海峡药学》 2017年第5期21-23,共3页 Strait Pharmaceutical Journal
关键词 硝苯地平 大鼠 体内药动学 生物利用度 Nifedipine Rats Pharmacokinetics Bioavailability
  • 相关文献

参考文献6

二级参考文献57

  • 1[1]Barrand MA,Bagrij T,Neo SY.Multidrug resistanceassociated protein:a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion [J].Gen Pharmac,1997,28:629-651. 被引量:1
  • 2[2]Loo T,Clarke DJ.The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface [J].Biol Chem,1999,274:24759-24765. 被引量:1
  • 3[3]Kramer R,Weber TK,Arceci R.Inhibition of N-linked glycosylation of P-glycoproptein by tunicamycin results in a reduced multidrug resistance phenotype [J].Br J Cancer,1995,71:760-676. 被引量:1
  • 4[4]Higgins CF.ABC transporters:from microorganisms to man[J].Ann Rev Cell Biol,1992,8:76-113. 被引量:1
  • 5[5]Cornwell MM,Safa AR,Felsted RL,et al.Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170- kua protein detected by photoaffinity labeling [J].Proc Natl Acad Sci USA,1986,83:3847-3850. 被引量:1
  • 6[6]Akiyama SI,Cornwell MM,Kuwano M,et al.Most drugs that reverse multidrug resistance also inhibitphotoaffinity labeling of P-glycoprotein by a vinblastine analog [J].Mol Pharmacol,1988,33:144-147. 被引量:1
  • 7[7]Richard B Kin.Drugs as P-glycoprotein substrates,inhibitors,and inducers [J].Drug Metab Rev,2002,34(1-2):47-54. 被引量:1
  • 8[8]Seelig A.A general pattern for substrate recognition by P-glycoprotein [J].Eur J Biochem,1998,251:252-261. 被引量:1
  • 9[9]Kim RB,Fromm MF,Wandel C,et al.The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors [J].J Clin Invest,1998,10:289-294. 被引量:1
  • 10[10]Sun J,Sakai S,Tauchi Y,et al.Determination of lipophilicity of two quinolone antibacterials,ciprofloxacin and grepafloxacin,in the protonation equilibrium [J].Eur J Pharm Biopharm,2002,54(1):51-58. 被引量:1

共引文献41

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部